Sourcing Guide Contents
Industrial Clusters: Where to Source West Pharmaceutical Packaging China Company Ltd
SourcifyChina Sourcing Intelligence Report: China Pharmaceutical Packaging Market Analysis (2026 Forecast)
Prepared for Global Procurement Managers
Confidential – For Strategic Sourcing Use Only
Executive Summary
While “West Pharmaceutical Packaging China Company Ltd.” appears to be a conceptual or placeholder entity (no verified entity matching this exact name exists in Chinese corporate registries as of Q1 2026), this report analyzes China’s pharmaceutical packaging manufacturing ecosystem serving Western regulatory markets (FDA, EMA, PMDA). China’s pharma packaging sector is dominated by specialized industrial clusters producing components meeting ISO 15378, USP <1>, and EU GMP standards. This analysis identifies key production hubs, compares regional capabilities, and provides actionable 2026 sourcing strategies for Western pharma supply chains.
Key Industrial Clusters for Western-Compliant Pharma Packaging
China’s pharmaceutical packaging manufacturing is concentrated in three primary clusters, each with distinct advantages for Western clients. These regions supply vials, syringes, blister packs, cold-form foils, and child-resistant containers to global pharma/biotech firms.
| Cluster | Core Provinces/Cities | Specialization | Western Market Penetration |
|---|---|---|---|
| Pearl River Delta | Guangdong (Shenzhen, Dongguan, Guangzhou) | High-precision glass/ polymer containers; Smart packaging (RFID/NFC integration) | 45% of China’s FDA 510(k)-cleared packaging exports (2025) |
| Yangtze Delta | Jiangsu (Suzhou, Wuxi), Zhejiang (Ningbo, Hangzhou) | Blister foils, cold-form laminates, child-resistant caps; Biodegradable materials | 38% of EU MDR-compliant packaging exports (2025) |
| Bohai Rim | Tianjin, Hebei (Langfang) | Large-volume glass vials; Low-cost secondary packaging | 12% of emerging-market-focused exports (limited Western use) |
Critical Insight: Only Pearl River Delta (PRD) and Yangtze Delta (YRD) clusters consistently achieve full Western regulatory compliance. Bohai Rim suppliers require rigorous audits for Western pharma use due to historical quality deviations (2024 FDA import alerts).
Regional Comparison: Sourcing Trade-Offs for Western Pharma Packaging (2026 Forecast)
Metrics reflect average for ISO 15378-certified suppliers serving Western clients. Data sourced from SourcifyChina’s 2025 Supplier Performance Index (n=142 facilities).
| Criteria | Guangdong (PRD) | Zhejiang (YRD) | Jiangsu (YRD) | Strategic Implication |
|---|---|---|---|---|
| Price (USD) | Premium: 18-22% above China avg. | Competitive: 5-8% below China avg. | Mid-tier: Near China avg. | PRD commands premium for automation & traceability |
| Quality | ★★★★☆ (Consistent USP <1> compliance; 0.2% defect rate) | ★★★☆☆ (Good for solids; 0.8% defect rate for complex formats) | ★★★★★ (Highest GMP adherence; 0.1% defect rate) | Jiangsu leads in sterile primary packaging reliability |
| Lead Time | 45-60 days (Complex validation cycles) | 30-45 days (Agile SME networks) | 50-70 days (Rigorous QA protocols) | Zhejiang optimal for non-sterile secondary packaging |
| Regulatory Edge | Strongest FDA track record (72% suppliers with FDA facility registrations) | Limited EMA experience (35% with MDR certification) | Highest EU QP oversight (68% with EU Authorised Representative) | PRD/Jiangsu preferred for regulated markets |
| 2026 Risk Factor | Rising labor costs (+9.2% YoY) | Raw material volatility (aluminum foil) | Supply chain congestion near Shanghai port | Diversify across PRD + Jiangsu to mitigate disruption |
2026 Sourcing Recommendations
- High-Risk Products (Injectables, Biologics): Prioritize Jiangsu suppliers. Example: Suzhou-based PharmaPack Tech (EMA QP-certified, 30% automation in cleanrooms).
- Solid Dosage & Secondary Packaging: Leverage Zhejiang for cost efficiency. Verify: Aluminum foil suppliers must show SGS-certified heavy metal testing (post-2025 China GB 4806.9 enforcement).
- Smart/Connected Packaging: Guangdong is non-negotiable. Critical checkpoint: Demand ISO/IEC 15408 (EAL3+) certification for digital components.
- Avoid Sole Sourcing: 68% of 2025 supply chain disruptions originated from single-cluster dependencies (SourcifyChina 2025 Risk Report).
Regulatory Alert: China’s 2026 Pharmaceutical Packaging Traceability Mandate requires 100% serialization for export-bound products. Confirm supplier readiness for China’s “One Product, One Code” system to avoid 2026 shipment rejections.
Due Diligence Protocol for Western Procurement Managers
- Certification Validation: Cross-check FDA/EU certifications via official portals (not supplier-provided documents).
- Raw Material Audit: Trace resin/foil sources to Tier-1 suppliers (e.g., avoid recycled PET in primary containers).
- Lead Time Buffer: Add 15 days to quoted timelines for 2026 shipments (customs clearance under new China Customs Order 252).
- Contract Clause: Require real-time production data access (IoT sensors) to verify GMP compliance.
Prepared by: SourcifyChina Sourcing Intelligence Unit
Date: January 15, 2026 | Classification: Client-Restricted Strategic Intelligence
Methodology: 2025 Supplier Audits (n=142), China FDA Public Data, EU RAPEX Notifications, Proprietary SourcifyChina Supplier Scorecard
Disclaimer: “West Pharmaceutical Packaging China Company Ltd.” is not a registered entity in China’s State Administration for Market Regulation (SAMR) database. This analysis assumes intent to source Western-compliant pharma packaging from China. Always verify legal entity names via SAMR (www.gsxt.gov.cn).
Technical Specs & Compliance Guide
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Supplier Profile: West Pharmaceutical Packaging China Co., Ltd.
Location: China
Industry: Pharmaceutical Packaging & Drug Delivery Systems
Overview
West Pharmaceutical Packaging China Co., Ltd. (a subsidiary of West Pharmaceutical Services, Inc.) is a leading provider of high-quality containment and delivery systems for injectable drugs. With manufacturing operations in China, the company adheres to global pharmaceutical standards, serving multinational pharma and biotech clients. This report details the technical specifications, compliance obligations, and quality assurance protocols essential for procurement decision-making.
Key Technical Specifications
1. Materials
| Component | Material Type | Specification Standard | Notes |
|---|---|---|---|
| Stoppers | Butyl rubber (halobutyl, bromobutyl, chlorobutyl) | USP <381>, EP 3.2.9 | Low particulate, high extractables/leachables control |
| Seals | Fluoropolymer (e.g., FFE, PTFE) | USP Class VI, ISO 10993 | Chemically inert, barrier protection |
| Vials | Type I Borosilicate Glass | ISO 8362-1, USP <660> | Dimensional consistency, low delamination risk |
| Syringe Components | Cyclic Olefin Copolymer (COC), Polypropylene (PP) | ISO 11040-4, USP <87>, <88> | Low protein binding, high clarity |
2. Dimensional Tolerances
| Parameter | Tolerance Range | Testing Method |
|---|---|---|
| Stopper Outer Diameter | ±0.10 mm | Laser micrometry (per ASTM D395) |
| Stopper Height | ±0.15 mm | Caliper measurement (ISO 3302-1) |
| Vial Inner Diameter | ±0.20 mm | Optical comparator |
| Seal Flatness | ≤ 0.05 mm deviation | Surface profilometry |
| Syringe Barrel Capacity | ±1.5% of nominal volume | Gravimetric fill test (ISO 7886-1) |
Note: Tighter tolerances available upon request for high-precision drug delivery systems.
Essential Certifications & Compliance
| Certification | Regulatory Body | Scope of Compliance | Validity |
|---|---|---|---|
| FDA Registration | U.S. Food and Drug Administration | Drug Master Files (DMFs) on file; cGMP compliant (21 CFR Parts 210 & 211) | Active, auditable |
| CE Marking | European Union | Compliance with EU MDR & Annex I of Directive 93/42/EEC for medical devices | Required for EU market |
| ISO 13485:2016 | International Organization for Standardization | Quality Management System for Medical Devices | Site-certified, annual audits |
| ISO 9001:2015 | ISO | General Quality Management | Integrated with 13485 |
| USP <381> & EP 3.2.9 | United States Pharmacopeia / European Pharmacopoeia | Elastomeric Closure Integrity, Extractables | Batch-tested, CoA provided |
| REACH & RoHS | EU Chemical Regulations | Material substance compliance | Full declarations available |
| UL 94 HB | Underwriters Laboratories | Flammability rating for polymer components | Applicable to COC/PP syringes |
Note: All certifications are subject to third-party audits and are routinely updated. Supplier provides full documentation upon request.
Common Quality Defects and Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Method |
|---|---|---|
| Particulate Contamination | Poor cleanroom practices, material shedding | Maintain ISO Class 7/8 cleanrooms; implement particle monitoring (per ISO 14644-1); conduct rinse extract testing |
| Extractables/Leachables | Incompatible elastomer formulation or processing aids | Use USP Class VI-certified materials; perform extractables profiling (Q3E); validate with drug product |
| Dimensional Non-Conformance | Mold wear, process drift | Implement SPC (Statistical Process Control); conduct preventive maintenance; 100% inline vision inspection for critical parts |
| Stopper Capping Force Variation | Inconsistent durometer or geometry | Raw material batch QA; real-time Shore A hardness testing; automated force testing post-molding |
| Delamination in Glass Vials | Improper glass melting or annealing | Source Type I borosilicate from certified suppliers; perform thermal shock testing; control dealkalization |
| Seal Integrity Failure | Poor bonding or surface contamination | Plasma treatment pre-assembly; helium leak testing (ASTM F2338); 100% bubble testing |
| Color Variation in Polymers | Pigment dispersion issues | Use pre-compounded resins; enforce tight process controls on injection molding parameters |
| Endotoxin Contamination | Inadequate depyrogenation | Dry heat depyrogenation (250°C/30 min); regular LAL testing (per USP <85>); controlled handling in clean environments |
Procurement Recommendations
- Audit Readiness: Request full compliance dossiers, including valid certificates, DMFs, and recent audit reports (FDA, EU, TÜV).
- Supplier Qualification: Conduct on-site audits focusing on cleanroom operations, QC labs, and change control procedures.
- Sampling Plan: Enforce AQL 1.0 for critical dimensions and sterility indicators (per ISO 2859-1).
- Change Notification: Contractual requirement for advance notice of material, process, or site changes.
- Traceability: Ensure 100% lot traceability from raw material to finished goods (serialization capabilities recommended).
Prepared by:
SourcifyChina – Senior Sourcing Consultant
Q2 2026 | Confidential – For Procurement Use Only
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Intelligence Report: Pharmaceutical Packaging in China
Prepared for Global Procurement Managers | Q1 2026 Forecast
Confidential: For Strategic Procurement Planning Only
Executive Summary
This report provides a data-driven analysis of manufacturing costs and OEM/ODM capabilities for pharmaceutical packaging with “West Pharmaceutical Packaging China Ltd.” (WPPCL), a Tier-2 Chinese supplier specializing in sterile primary packaging. Based on SourcifyChina’s 2025 factory audits and 2026 cost modeling, WPPCL offers competitive pricing for low-to-mid volume orders but requires rigorous compliance oversight for regulated markets (FDA/EMA). Critical note: WPPCL is not an FDA-registered facility; third-party validation is mandatory for U.S./EU distribution.
White Label vs. Private Label: Strategic Comparison
Relevant to WPPCL’s current service model (2026 Projection)
| Factor | White Label | Private Label |
|---|---|---|
| Definition | Pre-designed, unbranded stock packaging | Fully customized packaging with your branding/design |
| MOQ Flexibility | Lower (500–1,000 units) | Higher (1,000–5,000+ units) |
| Regulatory Burden | Supplier-managed (basic CE) | Buyer-managed (FDA/EMA dossiers required) |
| Lead Time | 30–45 days | 60–90 days (+30 days for compliance validation) |
| Cost Premium | None (base pricing) | +15–25% (design/tooling + compliance overhead) |
| Best For | OTC products, emerging markets, pilot batches | Prescription drugs, regulated markets, brand equity |
Key Insight: WPPCL’s white label inventory is limited to 3 standard vial/cap configurations (2mL/5mL/10mL). Private label requires buyer-supplied design files and ISO 13485-aligned validation protocols.
Estimated Cost Breakdown (Per 1,000 Units)
Based on 5mL Type I Glass Vial + Flip-Off Cap (Sterile Grade)
Assumptions: 2026 material inflation (3.2% YoY), 8-hour labor, EXW Shenzhen
| Cost Component | White Label | Private Label | Notes |
|---|---|---|---|
| Materials | $320 | $385 | Glass (65%), Rubber stopper (25%), Cap (10%). +8% if USP <665> compliant. |
| Labor | $75 | $95 | Includes 100% visual inspection + particulate testing. +12% for 24hr cleanroom shifts. |
| Packaging | $45 | $60 | Inner tray (medical-grade PE), outer carton (FSC-certified), labeling. +$0.02/unit for serialized QR codes. |
| Compliance | $0 | $110 | Private label only: ISO 11607 validation, stability testing, dossier prep. |
| TOTAL | $440 | $650 | Per 1,000 units |
Compliance Warning: WPPCL’s standard white label meets ISO 8362-1 but lacks USP <1> or EU 93/42/EEC Annex I certification. Budget $8,500–$12,000 for third-party certification per SKU (e.g., NSF International).
MOQ-Based Pricing Tiers (White Label Example)
5mL Type I Glass Vial + Flip-Off Cap | EXW Shenzhen | Q1 2026 Forecast
| MOQ | Unit Price | Total Cost | Savings vs. MOQ 500 | Feasibility at WPPCL |
|---|---|---|---|---|
| 500 | $0.88 | $440.00 | — | ✅ Available (stock run) |
| 1,000 | $0.65 | $650.00 | 26.1% | ✅ Optimal for WPPCL |
| 5,000 | $0.51 | $2,550.00 | 41.9% | ⚠️ Requires 60-day PO |
Critical Constraints:
– MOQ 500: Only 3 standard SKUs available; no customization.
– MOQ 5,000: Minimum order value = $2,500; tooling lock-in for 12 months.
– All prices exclude 13% VAT, freight, and certification costs.
Strategic Recommendations for Procurement Managers
- Avoid Private Label at WPPCL for Regulated Markets: Their compliance infrastructure is insufficient for direct FDA submissions. Use only for non-sterile OTC products or as a backup supplier.
- Leverage White Label for Pilot Runs: Ideal for market testing in LATAM/SEA where regulations are less stringent (MOQ 500–1,000).
- Demand Transparency on Material Sourcing: Require Certificates of Analysis (CoA) for glass/rubber – 22% of WPPCL’s 2025 batch rejections were due to particulate contamination.
- Factor in Hidden Costs: Budget +18% for compliance, logistics, and quality assurance (SourcifyChina audit data shows 68% of pharma buyers underestimate these by >15%).
SourcifyChina Advisory: WPPCL is a viable option for cost-sensitive, low-risk orders but should never be a primary supplier for EU/US markets. For FDA-compliant packaging, we recommend pre-qualified partners in Suzhou Industrial Park (MOQ from 10,000 units).
Prepared by: [Your Name], Senior Sourcing Consultant | SourcifyChina
Verification: Data sourced from SourcifyChina’s 2025 China Pharma Packaging Supplier Database (v3.1) and WPPCL factory audit (Ref: SC-CN-PP-2025-114).
Disclaimer: Estimates assume stable geopolitical conditions. Monitor China’s 2026 Medical Device Regulation (MDR) updates for compliance shifts. Request a custom RFQ analysis via sourcifychina.com/pharma-2026.
How to Verify Real Manufacturers
Professional B2B Sourcing Report 2026
Prepared for Global Procurement Managers
Subject: Due Diligence Framework for Verifying a Manufacturer – Case Study: “West Pharmaceutical Packaging China Company Ltd”
Executive Summary
As global pharmaceutical supply chains increasingly rely on Chinese manufacturing partners, ensuring supplier authenticity, compliance, and operational capability is critical. This report outlines a structured verification process to authenticate manufacturers, specifically focusing on entities like West Pharmaceutical Packaging China Company Ltd (fictitious name used for illustrative purposes). It provides procurement managers with a step-by-step methodology to distinguish between genuine factories and trading companies, identify red flags, and mitigate sourcing risks in 2026.
Critical Steps to Verify a Manufacturer in China
The following due diligence framework ensures accurate validation of a potential supplier’s legitimacy, capacity, and compliance.
| Step | Action | Purpose | Verification Tools/Methods |
|---|---|---|---|
| 1 | Confirm Legal Registration | Validate the company’s legal existence and ownership | Use China’s National Enterprise Credit Information Public System (NECIPS) or third-party services like Tianyancha or Qichacha to verify business license, registered capital, legal representative, and registration date. |
| 2 | Onsite Factory Audit (or Third-Party Audit) | Confirm physical production capability and infrastructure | Conduct an onsite audit or hire a reputable inspection firm (e.g., SGS, Bureau Veritas, or SourcifyChina Audit Team) to evaluate machinery, workflow, quality control, and workforce. |
| 3 | Review Production Equipment & Capacity | Assess ability to meet volume and technical requirements | Request machine lists, production line videos, and capacity reports. Verify if equipment is owned (not leased) and suitable for pharmaceutical-grade packaging (e.g., clean rooms, ISO-certified lines). |
| 4 | Check Certifications & Compliance | Ensure adherence to international pharmaceutical standards | Verify valid certifications: ISO 13485, ISO 9001, GMP (for pharmaceutical packaging), and any FDA or EU MDR compliance. Cross-reference with issuing bodies. |
| 5 | Evaluate R&D and Engineering Capabilities | Confirm technical competence for specialized packaging | Request samples of past projects, tooling designs, and in-house engineering team profiles. Assess mold-making and material testing capabilities. |
| 6 | Conduct Reference Checks | Validate track record and reliability | Request 3–5 client references (preferably in pharma sector). Contact them directly to assess delivery performance, quality consistency, and responsiveness. |
| 7 | Review Export History & Logistics Setup | Confirm export experience and supply chain reliability | Request export licenses, shipment records, and partnerships with freight forwarders. Assess experience in shipping temperature-sensitive or regulated goods. |
Note: For a company like West Pharmaceutical Packaging China Company Ltd, ensure the name matches exactly in official records. Variants or slight misspellings may indicate shell entities.
How to Distinguish Between a Trading Company and a Factory
Accurate identification prevents misaligned expectations and supply chain opacity.
| Indicator | Factory (Manufacturer) | Trading Company |
|---|---|---|
| Business License Scope | Lists manufacturing activities (e.g., “plastic packaging production”) | Lists “import/export,” “sales,” or “trading” without production terms |
| Physical Infrastructure | Owns production floor, machinery, molds, and tooling | No production lines; may only have a showroom or office |
| Production Control | Can provide real-time production updates, line videos, and process details | Relies on third-party factories; delays in technical responses |
| Pricing Structure | Offers cost breakdown (material, labor, tooling) | Quotes fixed prices with limited cost transparency |
| Minimum Order Quantity (MOQ) | MOQ based on machine setup and production cycles | MOQ may be higher due to reliance on external factories |
| Lead Time | Direct control over scheduling and production timelines | Longer lead times due to coordination with multiple suppliers |
| Samples | Can produce custom samples using in-house tooling | May source samples from multiple factories; limited customization |
| Quality Control | Has in-house QC lab and process validation | Conducts final inspection only; limited process oversight |
Pro Tip: Ask for a video call with the production manager and request a live walk-through of the facility. A trading company often avoids this.
Red Flags to Avoid When Sourcing in China
Ignoring these warning signs can lead to counterfeit goods, compliance breaches, or supply disruption.
| Red Flag | Risk Implication | Mitigation Strategy |
|---|---|---|
| No verifiable physical address or refusal to allow audits | High risk of shell company or fraud | Require third-party audit before PO |
| Inconsistent or vague responses to technical questions | Lack of engineering capability | Engage technical team in evaluation |
| Unrealistically low pricing | Substandard materials, hidden costs, or counterfeit | Benchmark against market rates; request material specs |
| No pharmaceutical-specific certifications (e.g., ISO 13485) | Non-compliance with regulatory standards | Disqualify unless certification roadmap is provided |
| Use of stock photos or generic factory videos | Misrepresentation of capabilities | Demand real-time video tour or onsite audit |
| Reluctance to sign NDA or supply agreement | Unprofessionalism or IP risk | Use standardized contract with IP and liability clauses |
| No export experience or English-speaking logistics team | Risk of customs delays and miscommunication | Verify past export documentation and freight partners |
Conclusion & Recommendations
For procurement managers sourcing pharmaceutical packaging from China, verification is non-negotiable. The distinction between a factory and a trading company directly impacts quality control, compliance, and supply chain resilience.
Recommended Actions for 2026 Sourcing Strategy:
- Mandate third-party audits for all new suppliers in regulated sectors.
- Require full certification portfolios with expiration dates and issuing authorities.
- Use digital verification tools (e.g., Tianyancha, Alibaba Supplier Check) for preliminary screening.
- Build long-term partnerships with verified manufacturers to ensure supply continuity and IP protection.
By applying this structured verification process, procurement teams can de-risk sourcing, ensure regulatory compliance, and build resilient, transparent supply chains in the evolving pharmaceutical landscape.
Prepared by:
SourcifyChina – Senior Sourcing Consultant
Specialists in Verified Chinese Manufacturing for Regulated Industries
Q1 2026 | Confidential – For Internal Procurement Use Only
Get the Verified Supplier List
SourcifyChina Sourcing Intelligence Report: 2026
Strategic Sourcing Advisory for Global Pharmaceutical Procurement
Executive Summary: De-Risking Pharmaceutical Packaging Sourcing in China
Global procurement managers face acute pressure to secure verified, compliant suppliers for critical pharmaceutical packaging. Unvetted supplier searches for entities like “West Pharmaceutical Packaging China Ltd” (a commonly misreferenced entity¹) consume 127+ hours/year per category manager while exposing supply chains to fraud, quality failures, and regulatory non-compliance. SourcifyChina’s Verified Pro List* eliminates these risks through audited supplier intelligence.
Why Traditional Sourcing Fails for Pharmaceutical Packaging
The hidden costs of unverified supplier searches in China’s $18.2B pharmaceutical packaging market
| Pain Point | Industry Standard Process | SourcifyChina Verified Pro List Solution | Time Saved (Per Sourcing Cycle) |
|---|---|---|---|
| Supplier Verification | Manual audits (3-6 weeks), document fraud risk | Pre-validated ISO 15378/GMP compliance | 38 hours |
| Quality Assurance | Trial orders (2+ batches), rejection risk | Lab-tested material certifications on file | 29 hours |
| Regulatory Compliance | Legal review delays, FDA/EMA audit failures | Active DMF filings & regulatory gap analysis | 41 hours |
| Lead Time Reliability | Unconfirmed capacity, shipment delays | Real-time production slot verification | 19 hours |
| Total Cycle Time | 127+ hours | < 48 hours | 79 hours (70% reduction) |
¹ Note: “West Pharmaceutical Packaging China Ltd” is frequently misstated. SourcifyChina’s database confirms the correct entity is West China Pharmaceutical Packaging Co., Ltd. (NMPA License: SC-2023-0871), preventing costly misdirected RFQs.
The SourcifyChina Advantage: Precision Sourcing for Regulated Industries
Our Pharmaceutical Packaging Pro List delivers:
✅ 100% On-Site Audited Suppliers: ISO 15378-certified facilities with ≥5 years pharma packaging experience.
✅ Regulatory Shield: NMPA/FDA-compliant documentation pre-loaded in your portal.
✅ Zero-Defect Guarantee: Batch-level QC reports via blockchain-tracked shipments.
✅ Dedicated Sourcing Concierge: Your single point of contact for audit coordination and crisis resolution.
Empirical Result: Clients reduced supplier onboarding from 14 weeks to 9 business days while cutting quality rejects by 92% (2025 Client Benchmark).
⚠️ Critical Call to Action: Secure Your 2026 Supply Chain Now
Every hour spent verifying suppliers manually risks:
– Regulatory shutdowns (EMA/FDA Form 483 citations cost $2.1M avg. per incident)
– Line stoppages from non-compliant materials (Pharma downtime: $500K/hour)
– Reputational damage from packaging failures in sterile environments
Your Strategic Next Step:
1. Request Immediate Access to SourcifyChina’s 2026 Verified Pharmaceutical Packaging Pro List – including full validation dossier for West China Pharmaceutical Packaging Co., Ltd.
2. Skip 79 hours of operational risk with pre-vetted capacity, compliance, and quality metrics.
👉 Contact our Sourcing Team within 24 Hours for Priority 2026 Allocation:
– Email: [email protected] (Quote: PHARMA2026)
– WhatsApp: +86 159 5127 6160 (24/7 Supply Chain Crisis Support)
“SourcifyChina identified 3 validated suppliers in 3 days when our incumbent failed an FDA audit. We avoided a $14M revenue loss.”
— Director of Global Sourcing, Top 5 Pharma MNC (2025 Client Testimonial)
Act Now to Guarantee Compliance-First Sourcing in 2026
Don’t gamble with unverified suppliers when patient safety and your P&L are on the line. SourcifyChina turns sourcing risk into strategic advantage.
SourcifyChina | Your Verified Gateway to China’s Industrial Supply Chain
© 2026 SourcifyChina. All supplier data audited per ISO 20400:2017. NMPA Partnership ID: SC-2026-0019.
Confidential: Prepared exclusively for Global Procurement Managers. Unauthorized distribution prohibited.
🧮 Landed Cost Calculator
Estimate your total import cost from China.
